Garg, D. (2026). Upfront low-dose diet-modified nilotinib versus standard imatinib in Indian patients with newly diagnosed chronic-phase chronic myeloid leukemia: The NILLOW phase II randomised trial.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.6584